A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2006
10/17/2006	US7122533 Cosalane compounds and methods for their use
10/17/2006	US7122532 Regulation of intracellular glucocorticoid concentrations
10/17/2006	US7122531 Regulation of intracellular glucocorticoid concentrations
10/17/2006	US7122530 24-hydroxyvitamin D, analogs and uses thereof
10/17/2006	US7122529 Administering compound; irradiation with light of selective wavelength; deactivating pathogens in blood
10/17/2006	US7122528 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
10/17/2006	US7122527 Use of antisense oligonucleotides to inhibit the expression of human Akt-1
10/17/2006	US7122526 Topoisomerase I inhibitors; such as 2,3-methylenedioxy-6-hydroxymethyl-9-hydroxy-12-(beta-D-glucopyranosyl) -6,7,12,13-tetrahydroindolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7-dione
10/17/2006	US7122525 Targeted therapeutics and uses thereof
10/17/2006	US7122518 Administering a quenching photosensitizer molecule for side effect reduction to retinal pigmented epithelium; age related macular degeneration
10/17/2006	US7122361 Compositions employing a novel human kinase
10/17/2006	US7122360 Polypeptides, polynucleotides and uses thereof
10/17/2006	US7122340 Regulatory T cells; methods
10/17/2006	US7122336 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
10/17/2006	US7122311 Diagnosing respiratory disorder; obtain cells, monitor expression of marker gene, determine sequence, compare to control, detect polymorphism in polypeptide or nucleotide, presence of polymorphism indicates respiratory disorders
10/17/2006	US7122308 Testing a sample from a patient for the presence of the s variant of the 5HTTLPR polymorphism in the 5HTT gene, the presence of which indicates increased susceptibility
10/17/2006	US7122214 Containing over 30 percent of total flavonoids; the naringin contained in the flavonoids is more than 30 percent
10/17/2006	US7122206 Spraying into nose; triamcinolone acetonide
10/17/2006	US7122204 Antibiotic composition with inhibitor
10/17/2006	US7122203 Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
10/17/2006	US7122197 Compounds from Moraxella catarrhalis
10/17/2006	US7122187 Treating autoimmune diseases with humanized anti-CD40L antibody
10/17/2006	US7122180 DNA vectors containing mutated HIV proviruses
10/17/2006	US7122173 A compound having slowly-deactivating A-type K+ channel opening activity such as N-(5,5-dioxido-10-oxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
10/17/2006	CA2489140C Dosage form containing pantoprazole as active ingredient
10/17/2006	CA2447405C Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
10/17/2006	CA2395705C Substituted phenyl-piperazine derivatives, their preparation and use
10/17/2006	CA2352964C A method for enhancing protective cellular responses to genotoxic stress in skin
10/17/2006	CA2339661C Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p
10/17/2006	CA2334120C Oral sustained-release preparation of fasudil hydrochloride
10/17/2006	CA2324919C Hiv inhibiting pyrimidine derivatives
10/17/2006	CA2322502C Protease inhibitors in absorbent articles
10/17/2006	CA2318527C Inhibitors of .alpha.4 mediated cell adhesion
10/17/2006	CA2317038C Supplement for dialysis patients
10/17/2006	CA2294744C Multiple unit effervescent dosage form
10/17/2006	CA2284976C Process for preparing single enantiomer narwedine
10/17/2006	CA2275686C Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
10/17/2006	CA2260065C Process for preparing 1-substituted 4-cyano-1,2,3-triazoles
10/17/2006	CA2253547C Benzofuryl derivatives and their use
10/17/2006	CA2250318C Sustained-release metal valproate tablets
10/17/2006	CA2244774C Dihydropyridine derivatives, their preparation and their use as adenosine receptor antagonists
10/17/2006	CA2241856C Agent for prophylaxis and treatment of diabetic complications
10/17/2006	CA2238818C 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists
10/17/2006	CA2238817C 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
10/17/2006	CA2236357C 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands
10/17/2006	CA2212888C A method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds
10/17/2006	CA2207622C Intravaginal drug delivery devices for the administration of 17.beta.-oestradiol precursors
10/17/2006	CA2207333C Use of nebivolol as an anti-atherogenic
10/17/2006	CA2197207C Hiv protease inhibitor combination
10/17/2006	CA2196880C Nervonic acid compositions
10/17/2006	CA2182981C Sublingual or buccal pharmaceutical composition
10/17/2006	CA2166530C Stimulation of tanning by dna fragments or single-stranded dna
10/17/2006	CA2148988C Filamentous bacteria extracts used as cosmetic agents against the ageing of skin
10/17/2006	CA2126305C New treatments using venlafaxine
10/17/2006	CA2125662C Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
10/17/2006	CA2087902C Liposome compositions of porphyrin photosensitizers
10/15/2006	CA2504382A1 Composition for improving blood fluidity
10/12/2006	WO2006108155A2 Process for the preparation of anastrozole
10/12/2006	WO2006108151A1 Crystalline forms of pregabalin
10/12/2006	WO2006108149A2 Substituted benzylamines as cyp2a inhibitors and uses thereof to treat nicotine dependence
10/12/2006	WO2006108147A1 Cholesterol as an antibiotic for streptococcus pneumoniae
10/12/2006	WO2006108120A1 Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
10/12/2006	WO2006108107A1 Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
10/12/2006	WO2006108103A1 Purine and imidazopyridine derivatives for immunosuppression
10/12/2006	WO2006108059A1 C-met modulators and methods of use
10/12/2006	WO2006108040A1 Substituted indoles and their use as integrin antagonists
10/12/2006	WO2006108039A2 Substituted azetidinones
10/12/2006	WO2006108022A1 Process for the induction of intramolecular migration of sulfates, phosphates, and other oxyanions
10/12/2006	WO2006108008A2 A method and composition for nutritionally improving glucose control and insulin action
10/12/2006	WO2006107957A2 Device and methods for treating paranasal sinus conditions
10/12/2006	WO2006107948A2 Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
10/12/2006	WO2006107941A1 DERIVATIVES OF [6,7-DIHYDRO-5HIMIDAZO [l,2-ALPHA] IMIDAZOLE-3-SULFONYL]-AZETEDINE-CARBOXYLIC ACIDS, ESTERS AND AMIDES AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS
10/12/2006	WO2006107936A1 The use of ezetimibe in the prevention and treatment of cholesterol gallstones
10/12/2006	WO2006107923A1 Substituted benzylimidazoles useful for the treatment of inflammatory diseases
10/12/2006	WO2006107902A2 Use of spirostenols to treat mitochondrial disorders
10/12/2006	WO2006107860A2 Dihydropyridine compounds and compositions for headaches
10/12/2006	WO2006107859A2 Dihydropyridine compounds for neurodegenerative diseases and dementia
10/12/2006	WO2006107853A2 Pyrazolopyridine-1,4-diamines and analogs thereof
10/12/2006	WO2006107851A1 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
10/12/2006	WO2006107825A2 Skin enrichment using coq10 as the delivery system
10/12/2006	WO2006107806A2 Stannsoporfin compositions and administration
10/12/2006	WO2006107784A1 Imidazopyridazine compounds
10/12/2006	WO2006107771A2 PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS
10/12/2006	WO2006107756A1 Pyrrolo [2,3-d] imidazoles for the treatment of hyperproliferative disorders
10/12/2006	WO2006107753A2 Pyrazolopyridines and analogs thereof
10/12/2006	WO2006107751A2 Combined therapy utilizing reduction of dna methyltansferase expression and/or activity and interferon
10/12/2006	WO2006107736A1 Extractability and bioavailability of the natural antioxidant astaxanthin from a green alga, haematococcus pluvialis
10/12/2006	WO2006107723A1 Oils of capsaicinoids and methods of making and using the same
10/12/2006	WO2006107661A1 Histamine h3 receptor agents, preparation and therapeutic uses
10/12/2006	WO2006107626A1 Desferrithiocin polyether analogues
10/12/2006	WO2006107561A1 Tetrahydrothiopyrano pyrazole cannabinoid modulators
10/12/2006	WO2006107528A1 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
10/12/2006	WO2006107478A2 Crystalline sodium salt of an hiv integrase inhibitor
10/12/2006	WO2006107451A2 Honokiol derivatives for the treatment of proliferative disorders
10/12/2006	WO2006107386A1 Method for inhibiting and/or treating vaginal infection
10/12/2006	WO2006107357A1 Improved formulations of fenofibrate containing menthol or a peg/poloxamer mixture
10/12/2006	WO2006107330A1 Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
10/12/2006	WO2006107316A1 Improved formulations of fenofibrate containing menthol or peg/poloxamer
10/12/2006	WO2006107258A1 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
10/12/2006	WO2006107257A1 Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives

1 ... 4050 4051 4052 4053 4054 4055 4056 4057 4058 4059 4060 4061 4062 4063 4064 4065 4066 4067 4068 4069 4070 ... 7860